Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Submits NDA For Lorcaserin To FDA
Arena Pharmaceuticals (Arena) has submitted a New Drug Application (NDA) to the FDA for Lorcaserin, the company’s drug candidate for weight management, including weight loss and maintenance of
Arena Pharmaceuticals (Arena) has submitted a New Drug Application (NDA) to the FDA for Lorcaserin, the company’s drug candidate for weight management, including weight loss and maintenance of
ARCA biopharma (ARCA) has submitted a study protocol for review under the FDA’s Special Protocol Assessment (SPA) process for the design of a clinical trial. The study is
Eisai has presented results of the investigational compound, eritoran tetrasodium (E5564), where it appeared to be well tolerated in patients with severe sepsis in a phase II trial
Lupin has settled all ongoing Hatch-Waxman litigation relating to Memantine tablets, Lupin’s generic version of Forest Laboratories’ Alzheimer disease treatment, Namenda tablets. Namenda tablet is intended for the
The Dow Chemical Company (Dow) has announced a new Pacific leadership team in the Asia Pacific region. Jim McIlvenny has been named senior vice president of performance products;
Mitsui Chemicals (MCI), Tohcello and Mitsui Chemicals Fabro, (Fabro) have entered into a Fundamental Agreement to study integration of film/sheet businesses of the three companies. Under the Fundamental
Air Liquide, through its subsidiary Shanghai Chemical Industry Park Industrial Gases (SCIPIG), has signed a new 15-year industrial gases contract with Bayer Polyurethanes (Shanghai)(BPUS). Reportedly, SCIPIG is expected
The Swedish Medical Products Agency has now approved Xerclear for treatment of cold sores. It is a topical treatment that has been demonstrated to prevent the incidence of
China Aoxing Pharmaceutical (China Aoxing) has received the Good Manufacturing Practice (GMP) re-certification of four dosage forms, including capsule, tablet, granule and oral solution formulations, at its new
Isis will receive a $10m payment from OncoGenex Pharmaceuticals as a result of OncoGenex’ license of OGX-011 to Teva. OGX-011 is an antisense drug co-discovered by Isis and